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INTRODUCTION
The neurotransmitter serotonin, or 5-hydroxytryptamine (5-HT), is implied in several functions of the central nervous system, such as regulation of mood. Antidepressants, like selective serotonin reuptake inhibitors, increase the levels of serotonin in the synaptic cleft by blocking the serotonin transporter or by occupying the serotonin receptors. 5-HT synthesis may be an important aspect in the efficacy of antidepressants, as enough 5-HT should be produced for replenishing 5-HT stocks. [1] [2] [3] Serotonin is produced by neurons, of which the cell bodies lie in the raphe nuclei and project to almost every region of the brain. Serotonin is synthesized from the amino acid tryptophan (Trp), mainly in synaptic endings. This process takes place in two enzymatic steps. First, Trp is converted to 5-hydroxytryptophan (5-HTP) by the enzyme tryptophan hydroxylase (TPH). Second, 5-HTP is converted to 5-HT by aromatic amino acid decarboxylase (AADC). 5-HT is transported into vesicles by the vesicular monoamine transporter. When serotonergic neurons fire, such vesicles fuse with the synaptic membrane to release 5-HT into the synaptic cleft. Released serotonin can be pumped back into the nerve endings by serotonin transporter, and can either be stored in the vesicles or be degraded by monoamine oxidase to 5-hydroxyindoleacetic acid (5-HIAA), which leaves the brain through the cerebrospinal fluid.
Besides activity of the enzymes involved in 5-HT synthesis, several other processes may influence the production of 5-HT. The availability of Trp for 5-HT production is the rate-limiting step in this metabolic pathway. 4, 5 Trp is transported over the blood-brain barrier by the large neutral amino acid transporter (LAT). Transported Trp is not only used for 5-HT synthesis, but also incorporated into proteins and used for the production of kynurenine. The rate-limiting step in kynurenine production is the activity of the enzyme indoleamine 2,3-dioxygenase. Increased activity of indoleamine 2,3-dioxygenase may result in reduced availability of Trp for serotonin synthesis. 6 As direct measurement of serotonin synthesis is difficult, indirect estimates are commonly employed. 5-HT turnover rates can be measured by determining 5-HIAA concentrations or the 5-HTP/5-HIAA ratio in cerebrospinal fluid. 7 However, this is an invasive method, as a lumbar puncture is necessary to obtain cerebrospinal fluid. Another method is measurement of the levels of 5-HT in blood platelets, as 5-HT is synthesized within these cells in a way similar to neurons. The validity of this procedure is questionable, for peripheral levels of 5-HT may not reflect corresponding levels in the brain. [8] [9] [10] The only direct and non-invasive methods for measuring metabolic processes in the living brain are positron emission tomography (PET) and single-photon emission computed tomography. Several PET tracers have been produced for this purpose. 7 Radiolabeled Trp is not optimal, as Trp is also incorporated into proteins and used in the kynurenine pathway, rather than being used for 5-HT synthesis. 11 Tracer incorporation into proteins can be avoided by using a radiolabeled analog of Trp. Diksic and colleague's labeled a-methyltryptophan (AMT) with carbon-11.
12-17 However, AMT can still enter the kynurenine pathway. 18, 19 The trapping of radioactivity in the brain regions represents the production of [
11 C]5-HT and its metabolite [ 11 C]5-HIAA. When the enzyme monoamine oxidase, converting 5-HT to 5-HIAA, is inhibited in monkeys, the trapping of radioactivity is unchanged. 24 This indicates that within a period of 60 minutes, there is no significant loss of radiolabeled metabolites from monkey brain, and the trapping of 11 C reflects 5-HT synthesis. Inhibition of AADC, and thus the conversion of 5-HTP to 5-HT, reduces the value of k 3 , which suggests that this rate constant is closely related to the decarboxylation of [
11 C]5-HTP. 24 Positron emission tomography studies with [ 11 C]5-HTP have only been performed in monkeys or humans. To our knowledge, only one study applied [
11 C]5-HTP in rodents. 25 Rats were killed 40 minutes after [
11 C]5-HTP injection and radioactive metabolites in the striatum and cerebellum were determined by highperformance liquid chromatography. The results of this analysis raise the question whether pharmacologically induced changes of 5-HT synthesis in the rodent brain can be detected also with PET. If so, small animal imaging could be used to examine the mechanism of action of antidepressants.
The enzymatic steps in 5-HT synthesis can be inhibited by administering various drugs, thus one could investigate what [ 11 C]5-HTP is exactly measuring. Levels of the precursor Trp can be reduced by feeding animals a special, Trp-free diet, lacking Trp but containing identical levels of other amino acids as the control diet. As Trp is the direct precursor of 5-HT, we expect a decrease of 5-HT synthesis in animals fed a Trp-free diet. The first enzymatic step in 5-HT synthesis, hydroxylation of Trp by TPH, can be inhibited by para-chlorophenylalanine (PCPA), which strongly reduces 5-HT content in the rat brain. 26 As PCPA treatment reduces the conversion from Trp to 5-HTP, 5-HT synthesis should decrease as well. The second step in 5-HT synthesis, decarboxylation of 5-HTP by AADC, can be inhibited in peripheral organs by carbidopa, without affecting AADC activity in the brain. 27 Treatment of animals with carbidopa should not influence cerebral rates of 5-HT synthesis, but only reduce the peripheral metabolism of 5-HTP. When peripheral metabolism of [ 11 C]5-HTP is reduced, more parent tracer becomes available for uptake in the brain. A final compound, NSD 1015, inhibits AADC activity both in the brain and periphery. 28 Treatment of animals with NSD 1015 should decrease 5-HT synthesis rates in rat brain, as the production of 5-HT from 5-HTP is directly inhibited. An overview of the manipulations used in this study is presented in Figure 1 .
Thus, we performed the current study that is aimed at answering the following questions: (1) Can [ Tracer and Drug Treatment 22 The average injected dose of [ 11 C]5-HTP was 12.0 ± 6.4 MBq with a specific radioactivity of 23.4±11.2 GBq/mmoL. All drugs were administered by i.p. injection. Carbidopa was dissolved in water (1 mg/mL or 2.5 mg/mL), and doses of 1 or 10 mg/kg were administered 1 hours before tracer injection. NSD 1015 was dissolved in saline at 100 mg/mL, and a dose of 100 mg/kg was administered 30 minutes before tracer injection. Para-chlorophenylalanine (PCPA) was dissolved in saline at 150 mg/mL and a single dose of 150 mg/kg was administered on the two consecutive days before PET scanning. The second PCPA administration took place 24 hours before tracer injection.
In the initial part of this project, the dose-dependent effect of carbidopa was examined by treating groups of animals with 0, 1 or 10 mg/kg carbidopa. In the second part of the study, all animals were treated with 10 mg/kg carbidopa. Separate groups of animals were used for metabolite analysis.
MicroPET Acquisition and Image Reconstruction
Animals were anesthetized with isoflurane (5% in medical air for induction, 2% for maintenance). A cannula was placed in the left femoral artery to 11 C]5-HTP follows the same pathway as endogenous 5-HTP. Different treatments can be used to manipulate different aspects of the 5-HT synthesis pathway. In this study, we used a Trp low diet (Trp À diet) to deplete rats from the 5-HT precursor. Carbidopa was used to inhibit peripheral AADC, and NSD 1015 was used to inhibit both peripheral and central AADC. Para-chlorophenylalanine (PCPA) was used to inhibit TPH. The different kinetic modeling rates are represented in purple. Adjusted from Visser et al. Co source was made, to allow correction of the PET images for attenuation and scatter. Tracer solution was injected through the penile vein. MicroPET data was acquired, using a list mode protocol of 96 minutes. The camera was started at the moment of injection of the first animal, whereas the second animal was injected after 6 minutes. During microPET scanning, 15 arterial blood samples (volume 0.1 to 0.15 mL) were drawn at different time-points: 15, 30, 45, 60, 75, and 90 seconds; 2, 3, 5, 7.5, 10, 15, 30, 60, and 90 minutes. The 15 blood samples for determination of input curves were centrifuged for 5 minutes at 13,000 rpm. Plasma was collected (25 mL) and radioactivity was measured in a calibrated g-counter.
List mode data were reframed into 8 frames of 30 seconds, 3 of 60 seconds, 2 of 120 seconds, 2 of 180 seconds, 3 of 300 seconds, 3 of 600 seconds, 1 of 720 seconds, and 1 of 960 seconds. Data of each frame were reconstructed employing an iterative algorithm (OSEM2D with Fourier rebinning, 4 iterations, and 16 subsets). The final data sets consisted of 95 slices with a thickness of 0.8 mm and an in-plane image matrix of 128 Â 128 pixels. Voxel size was 0.5 mm Â 0.5 mm Â 0.8 mm. Linear resolution of the images at the center of the field-of-view was B1.5 mm.
Ex vivo Biodistribution
After scanning, animals were killed by extirpation of the heart under deep isoflurane anesthesia and blood was collected. The blood was centrifuged for 10 minutes at 6,000 rpm, and plasma and a cell fraction were collected separately. Samples of different tissues were taken and weighed. Radioactivity in all samples was measured in a g-counter. Standard uptake values (SUV) were calculated using the formula:
The following brain regions were dissected: bulbi olfactorii, hippocampus, striatum, cortex, pons, medulla, cerebellum, and the rest of the brain.
Tryptophan Concentration
Blood samples were taken after extirpation of the heart, and plasma was collected as mentioned above. Approximately 0.3 mL of plasma was pipetted on an Amicon ultrafilter with 25 kDa cut-off. Free and bound Trp were separated by 30 minutes of centrifugation at 3,000 rpm. The ultrafiltrate was frozen ( À 201C) to determine free Trp at a later moment. A sample of unfiltered plasma was used to assess total Trp. Free and total Trp were measured as described previously. 29 Metabolite Analysis
In separate groups, blood samples (0.8 to 1.5 mL) were drawn for metabolite analysis at 5, 10, 20, 40, and 60 minutes after tracer injection. The blood was centrifuged (2 minutes at 13,000 rpm). Plasma was collected and 5% perchloric acid was added. After Vortex mixing, proteins were removed by 2 minutes of centrifugation at 13,000 rpm. The supernatant was analyzed by high-performance liquid chromatography, using an X-Terra C18-column (Waters, 4.6 Â 250 mm). The high-performance liquid chromatograph was equipped with a UV detector (set at 254 nm). Parent [ 11 C]5-HTP was separated from radioactive metabolites using gradient elution (buffer A: 50 mmol/L potassium dihydrogen phosphate, pH 3.3, buffer B: 30% acetonitrile in buffer A). The gradient was programmed as follows: 0 to 2 minutes 90% A and 10% B; 2 to 10 minutes 60% A and 40% B; 10 to 10.1 minutes 0% A and 100% B; 10.1 to 15 minutes 0% A and 100% B; 15 to 15.1 minutes 90% A and 10% B; 15.1 to 17 minutes 90% A and 10% B. Flow rate was 1 mL/minute and the gradient was linear.
The eluate was collected by a fraction collector, every 30 seconds and every 20 seconds during peak collection, and measured in a g-counter.
Fractions of parent tracer and metabolites were calculated from the radiochromatograms.
MicroPET Data Analysis
A volume of interest of the whole brain was drawn on a template of the rat brain (rat scanned with [
11 C]verapamil and treated with cyclosporine). Positron emission tomography images were re-aligned to this template, and the volume of interest was used to calculate time-activity curves (TACs). Model fits to these TACs were performed using in-house MatLab software. Using metabolite-corrected plasma data as input function, a onetissue compartment model or a 2TCM with irreversible tracer trapping were applied to fit the TACs. Blood volume was fixed to 3.6%. 30 Only the first 62 minutes of the scans were analyzed. As Patlak analysis requires an equilibrium state, which is reached after 20 minutes, a 40 minutes data set is too short. When a longer (90 minutes) data set was used, there is a higher chance of washout of [ 11 C]5-HIAA from the brain. We therefore used 62 minutes of data. The accumulation constant, K acc , was calculated with the formula:
A Patlak plot of the data was also made, as this graphical method can also be used to estimate the accumulation constant independent of the specific trapping model. 31, 32 Statistical Analysis Metabolite Analysis For all groups, metabolite analysis was performed. There was a significant difference in metabolism between the different treatment groups (repeated measures ANOVA, F ¼ 93.74, Df ¼ 5, Po0.0001). After Bonferroni posttests, it appeared that 10 mg/kg carbidopa decreased metabolism (also in combination with the other treatments). After metabolite correction, there was a significant difference between plasma curves (repeated measures ANOVA, F ¼ 9.96, Df ¼ 5, Po0.0001). After Bonferroni posttest, it appeared that this significant difference was present between almost all treatment groups, but only in the early time-points of the plasma peak. See Figure 2 for metabolite and metabolite-corrected plasma curves.
Tracer Uptake As visual inspection of microPET images and biodistribution data indicated a homogeneous uptake of uptake was observed between animals treated with 0 mg/kg and 10 mg/kg carbidopa ( Figure 3A ). Biodistribution data also indicated a significant increase of tracer SUV in the brain after carbidopa treatment (2-way ANOVA, F ¼ 49.89, Df ¼ 2, Po0.0001). Comparison of the different doses with Bonferroni posttests revealed that the SUV in the cortex was increased in animals treated with 1 mg/kg carbidopa, as compared with untreated controls, with an average SUV of 0.48±0.07 for animals treated with 1 mg/kg carbidopa versus 0.15 ± 0.02 for untreated animals. Trends towards an increase were also seen in the hippocampus, cerebellum, pons, medulla, and the rest of the brain. At the higher dose used (10 mg/kg), carbidopa increased tracer uptake in all studied brain regions, although the change in striatum and hippocampus did not reach statistical significance ( Figure 4A ). As the effect of carbidopa appeared to be dosedependent, we used 10 mg/kg carbidopa in all subsequent experiments to increase tracer delivery to the brain.
Brain TACs indicated no significant difference in Figure 4B ). Analysis of tracer uptake in the peripheral organs indicated a significant increase of radioactivity due to carbidopa treatment (two-way ANOVA, F ¼ 4.73, Df ¼ 2, P ¼ 0.0095). Bonferroni posttest revealed an increased radioactivity in the urine after treatment of animals with 1 mg/kg carbidopa, although a large individual variation was observed. The higher dose of 10 mg/kg had the opposite effect, as the amount of radioactivity in the urine was tremendously reduced. Carbidopa did not affect tracer uptake in any of the other organs, although uptake in the red blood cells and pancreas tended to be increased after treatment with 10 mg/kg carbidopa, compared with untreated controls ( Figure 4C) .
Para-chlorophenylalanine reduced [ 11 C]5-HTP uptake in the pancreas and increased radioactivity in the kidney and urine (twoway ANOVA, F ¼ 13.49, Df ¼ 3, Po0.0001). Feeding rats a low-Trp diet also increased tracer elimination via the renal route ( Figure 4D ).
Kinetic Modeling A 2TCM fitted whole brain TACs better than a one-tissue compartment model, as shown by lower values of the Akaike criterion (AICc corrected for small sample size; paired t-test, t ¼ 9.07, Df ¼ 46, Po0.0001), although both fits were good with an average Akaike value of 239±1.8 for the one-tissue compartment model and 225 ± 2.6 for the 2TCM. Cerebral blood volume was fixed at 3.6% in kinetic modeling, to avoid model fits with physiologically irrelevant high values (410%) for blood volume. In some cases, fixing the blood volume also resulted in a visually better fit.
Calculated values for the Patlak rate constant correlated well with K acc (r ¼ 0.733, P ¼ 0.0001), therefore only K acc is presented in Figure 5 . Data analysis with one-way ANOVA revealed that carbidopa treatment did not result in significant changes in K acc (F ¼ 0.13, Df ¼ 2, P ¼ 0.88) ( Figure 5A ). NSD 1015, PCPA, and Trp depletion did not result in significant changes of K acc either, although a trend towards a decrease was seen after 2 days of treatment with PCPA (one-way ANOVA, F ¼ 2.76, Df ¼ 3,
Inter-individual variation of K 1 and K 2 was high in all groups, but values for k 3 were more stable. As this rate constant possibly reflects the enzymatic activity of AADC, it is of equally great interest as K acc . There was no significant effect of carbidopa treatment on k 3 (one-way ANOVA, F ¼ 0.9767, Df ¼ 2, P ¼ 0.40) ( Figure 5C ). There was a significant effect of other treatments on k 3 (one-way ANOVA, F ¼ 3.26, Df ¼ 3, P ¼ 0.04), attributable to a reduction in k 3 after PCPA treatment (Dunnet's multiple comparison, q ¼ 2.70, Po0.05) ( Figure 5D ). None of the other constants 11 C]5-HTP in the pancreas and increased uptake in the kidney and urine. Tryptophan (Trp) depletion also increased the uptake in the kidney and urine. Abbreviations A/B: Bulb, bulbus olfactorii; Crtx, cortex; Str, striatum, Hip, hippocampus; Cer, cerebellum; Po, pons; Me, medulla; RB, rest brain. Abbreviations C/D: He, heart; Lu, lung; Li, liver; Sp, spleen; Pa, pancreas; Is, intestine small; Il, Intestine large; Ki, kidney; Ag, adrenal gland; Ad, adipose tissue; Bo, bone; Mu, muscle; Su, submandibular gland; Ur, urine; Bl, bladder; Pl, plasma; RBC, red blood cells. *Po0.05; **Po0.01; ***Po0.001. (K 1 or K 2 ) showed significant difference between groups, which is probably caused by the high variability between individual animals. The kinetic modeling data are summarized in Table 1 .
DISCUSSION
This study focused on two questions: (1) 25 Both the microPET and biodistribution data indicate that carbidopa increases brain uptake (SUV) in a dose-dependent way, with the greatest effect occurring at a dose of 10 mg/kg. Increased tracer uptake in the brain could result from a decrease in the peripheral breakdown of [
11 C]5-HTP. The reduction of urinary radioactivity after carbidopa treatment, indicating decreased tracer excretion, confirmed this hypothesis. Carbidopa treatment does not influence K acc or k 3 , indicating that AADC activity in the brain is the same as under control conditions. Therefore, we used 10 mg/kg carbidopa in all other treatment groups.
We expected to observe a large reduction of [ 11 C]5-HTP trapping after inhibition of AADC in the brain with NSD, as this enzyme converts [
11 C]5-HTP to [ 11 C]5-HT. Surprisingly, 100 mg/kg of NSD had no significant effect on tracer trapping. After inhibition of AADC with NSD, the total uptake of radioactivity may not be altered, because of the fact that PET cannot distinguish between [
11 C]5-HT and [ 11 C]5-HTP. In order to see differences in k 3 or K acc , [
11 C]5-HTP should exit the brain and not be trapped. Such trapping was in fact measured in rat brain by Lindner et al. 25 In a study with [
11 C]5-HTP in monkeys, the brain uptake of radioactivity was even increased after administration of NSD 1015, although a decrease in K acc was observed. 33 The observed increase of radioactivity in monkey brain could be due to inhibition of peripheral AADC by NSD 1015, an effect which we also observed in rats after carbidopa treatment. There seems to be a species difference between monkeys and rats, where the k 3 in monkeys is influenced by NSD 1015 and in rats, it is not.
Besides NSD 1015, we examined the effect of PCPA, an inhibitor of the enzyme TPH, which is located upstream in the 5-HT 34 However, this competition should influence the K 1 (and thus K acc ), but not the decarboxylase activity rate constant of AADC (k 3 ). Another explanation is that reduced 5-HT synthesis (by inhibition of the rate-limiting enzyme TPH) also influences enzymatic activity more downstream, e.g. AADC activity.
Trp depletion did not affect the brain uptake of [ 11 C]5-HTP, although it increased tracer excretion via the renal route. We expected to see a decrease in the levels of total and free (unbound) Trp in plasma, but only the free fraction was found to show a decline. The relatively minor effect of the low-Trp diet on plasma levels of free Trp explains why we could not measure any effect on serotonin synthesis rates in the brain.
An interesting observation in biodistribution studies was the high specific trapping of radioactivity in the pancreas. This may be physiologically meaningful, because 5-HT regulates insulin secretion by b-cells in the islets of Langerhans. 35 Indeed, both in vitro and in vivo studies of our laboratory have shown that serotonin synthesis and trapping of [
11 C]5-HTP and its metabolites in rat pancreas are specific to the b-cells compared with exocrine cells. 36 So this may be an interesting finding for future studies on imaging of pancreatic b-cells.
In summary, almost all results indicate that assessment of the validity to use [
11 C]5-HTP-PET as a measure for 5-HT synthesis rates in rat failed to convincingly show alterations in response to various interventions. Drug effects on enzyme and transport activities in the metabolic pathway of [
11 C]5-HTP cannot always be distinguished, probably causing the aforementioned problem. Kinetic modeling is based on a mathematical approximation, and it may be hard to relate individual k values to a physiologic process. A simplified model, like the 2TCM, may pool multiple metabolic steps into a single mathematical compartment and the data presented here does not allow us to accurately decompose this process. This is probably also the reason why Lindner et al. 25 could find a difference in k 3 after NSD 1015 treatment, as they quantified all the different metabolites of [ 11 C]5-HTP post mortem, in brain homogenates. Thus, they knew exactly how much radioactivity belonged to a certain compartment of the kinetic model. A PET camera cannot distinguish different radioactive species, and although K 4 seems negligible, other processes like transport and retention of unmetabolized [
11 C]5-HTP could influence the model parameters. Eventually, this may lead to ambiguity of the individual k values. A major source of variation may be the low uptake of [
11 C]5-HTP in rat brain. Although our data indicate that [
11 C]5-HTP is not useful for measuring serotonin synthesis in rat brain, the tracer may be useful in primates, as inhibitors of central AADC reduce the measured values of k 3 and K acc in monkeys. 33 
CONCLUSION

Further validation of [
11 C]5-HTP for measurement of 5-HT synthesis rates in human brain is definitely of great interest, especially for evaluation of 5-HT synthesis rates in patients with major depression. But based on our current data, [ 11 C]5-HTP and microPET are not suitable for pharmacodynamic studies in the rodent brain.
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